Combining the strength of genomics, nanoparticle technology, and direct intraductal delivery for breast cancer treatment

详细信息    查看全文

• 作者：Wei Wen Teo (1)
  Saraswati Sukumar (1)
  
  1. Breast Cancer Program ; Sidney Kimmel Comprehensive Cancer Center ; Johns Hopkins University School of Medicine ; 1650 ; Orleans Street ; CRB1/143 ; Baltimore ; MD ; 21231 ; USA
  
• 刊名：Breast Cancer Research
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：16
• 期：2
• 全文大小：123 KB
• 参考文献：1. Brock, A, Krause, S, Li, H, Kowalski, M, Goldberg, MS, Collins, JJ, Ingber, DE (2014) Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice. Sci Transl Med 6: pp. 212-217 CrossRef
  2. Miller, VM, Xia, H, Marrs, GL, Gouvion, CM, Lee, G, Davidson, BL, Paulson, HL (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 100: pp. 7195-7200 CrossRef
  3. Schwarz, DS, Ding, H, Kennington, L, Moore, JT, Schelter, J, Burchard, J, Linsley, PS, Aronin, N, Xu, Z, Zamore, PD (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2: pp. e140 CrossRef
  4. Sivaraman, L, Gay, J, Hilsenbeck, SG, Shine, HD, Conneely, OM, Medina, D, O鈥橫alley, BW (2002) Effect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumorigenesis. Breast Cancer Res Treat 73: pp. 75-83 CrossRef
  5. Murata, S, Kominsky, SL, Vali, M, Zhang, Z, Garrett-Mayer, E, Korz, D, Huso, D, Baker, SD, Barber, J, Jaffee, E, Reilly, RT, Sukumar, S (2006) Ductal access for prevention and therapy of mammary tumors. Cancer Res 66: pp. 638-645 CrossRef
  6. Chun, YS, Bisht, S, Chenna, V, Pramanik, D, Yoshida, T, Hong, SM, de Wilde, RF, Zhang, Z, Huso, DL, Zhao, M, Rudek, MA, Stearns, V, Maitra, A, Sukumar, S (2012) Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis 33: pp. 2242-2249 CrossRef
  7. Stearns, V, Mori, T, Jacobs, LK, Khouri, NF, Gabrielson, E, Yoshida, T, Kominsky, SL, Huso, DL, Jeter, S, Powers, P, Tarpinian, K, Brown, RJ, Lange, JR, Rudek, MA, Zhang, Z, Tsangaris, TN, Sukumar, S (2011) Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci Transl Med 3: pp. 106-108 CrossRef
  8. Love, SM, Zhang, W, Gordon, EJ, Rao, J, Yang, H, Li, J, Zhang, B, Wang, X, Chen, G (2013) A feasibility study of the intraductal administration of chemotherapy. Cancer Prev Res (Phila) 6: pp. 51-58 CrossRef
  9. Chun, YS, Yoshida, T, Mori, T, Huso, DL, Zhang, Z, Stearns, V, Perkins, B, Jones, RJ, Sukumar, S (2012) Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors. Breast Cancer Res Treat 135: pp. 201-208 CrossRef
  10. Ma, XJ, Salunga, R, Tuggle, JT, Gaudet, J, Enright, E, McQuary, P, Payette, T, Pistone, M, Stecker, K, Zhang, BM, Zhou, YX, Varnholt, H, Smith, B, Gadd, M, Chatfield, E, Kessler, J, Baer, TM, Erlander, MG, Sgroi, DC (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 100: pp. 5974-5979 CrossRef
  11. Hannemann, J, Velds, A, Halfwerk, JB, Kreike, B, Peterse, JL, van de Vijver, MJ (2006) Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 8: pp. R61 CrossRef
  
• 刊物主题：Cancer Research; Oncology;
• 出版者：BioMed Central
• ISSN：1465-5411

文摘

A large number of genes are altered in cancer cells. Often, reversal or inhibition of just one of these alterations leads to death of the cancer cells. Technological advances in multiple areas are necessary to potentiate clinical translation of these findings. In a recent article, Brock and colleagues reported that overexpressed HOXA1 is a critical event in tumor progression in a mouse mammary tumor model. They developed HOXA1-small interfering RNA nanoparticles and achieved effective therapeutic doses by delivering them intraductally through the nipple to the site of the tumor and at the same time circumvented the systemic immune response. This study strengthens the concept of targeting overexpressed genes by using small interfering RNA and bypassing systemic immunity through local intraductal delivery.